{
    "url_original": "https://www.wsj.com/articles/johnson-johnson-suspends-covid-vaccine-sales-guidance-citing-supply-surplus-11650368510?mod=business_lead_pos2",
    "url": "johnson-johnson-suspends-covid-vaccine-sales-guidance-citing-supply-surplus-11650368510",
    "title": "Johnson & Johnson Suspends Covid Vaccine Sales Guidance, Citing Supply Surplus",
    "sub_head": "In its consumer business, sales were hampered by supply constraints that mostly held back the company’s skin-care and beauty-product lines",
    "category_1": "Business",
    "category_2": "Earnings",
    "time": "2022-04-19 09:13:00",
    "body": "Johnson & Johnson  suspended full-year guidance for sales of its Covid-19 vaccine, citing a global surplus of doses and uncertainty over how the course of the pandemic will affect demand.<br />The healthcare-products company said Tuesday that Covid-19 shots helped left overall sales in its most recent quarter. Johnson & Johnson sold $457 million of the vaccine in its most recent quarter, with international buyers accounting for most of those sales. In the same period a year earlier, shortly after the shot had been authorized in the U.S., the company’s Covid-19 vaccine sales were $100 million, exclusively in the U.S. In the previous quarter, the company’s global Covid-19 vaccine sales came in at $1.62 billion."
}